<?xml version="1.0" encoding="UTF-8"?>
<ref id="bjh15394-bib-0021">
 <mixed-citation publication-type="journal" id="bjh15394-cit-0021">
  <string-name>
   <surname>Gupta</surname>, 
   <given-names>N.</given-names>
  </string-name>, 
  <string-name>
   <surname>Yang</surname>, 
   <given-names>H.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hanley</surname>, 
   <given-names>M.J.</given-names>
  </string-name>, 
  <string-name>
   <surname>Zhang</surname>, 
   <given-names>S.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liu</surname>, 
   <given-names>R.</given-names>
  </string-name>, 
  <string-name>
   <surname>Kumar</surname>, 
   <given-names>S.</given-names>
  </string-name>, 
  <string-name>
   <surname>Richardson</surname>, 
   <given-names>P.G.</given-names>
  </string-name>, 
  <string-name>
   <surname>Skacel</surname>, 
   <given-names>T.</given-names>
  </string-name> &amp; 
  <string-name>
   <surname>Venkatakrishnan</surname>, 
   <given-names>K.</given-names>
  </string-name> (
  <year>2017b</year>) 
  <article-title>Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: clinical and model‐based analyses</article-title>. 
  <source xml:lang="en">Target Oncology</source>, 
  <volume>12</volume>, 
  <fpage>643</fpage>–
  <lpage>654</lpage>.
 </mixed-citation>
</ref>
